Inflammatory Bowel DiseasesCOLORIZENCT06892990
Texture and Color Enhancement Imaging (TXI) for Inflammation Assessment in Patients With Inflammatory Bowel Diseases
A study testing TXI mode vs. WLE mode in people with Inflammatory Bowel Diseases and Colitis, Ulcerative, run by University of Ulm at 1 site in Germany.
Trial summary
In the context of the COLORIZE study, it is being tested whether the endoscopic light mode Texture and Color Enhancement Imaging (TXI) is non-inferior to the standard White Light Endoscopy (WLE) in assessing inflammatory activity in patients with Inflammatory Bowel Disease (IBD). Read more about this study
- Who is it for?
- Ages 18 years and older
- Conditions the study is for
- Inflammatory Bowel Diseases, Colitis, Ulcerative, Crohn Disease
- What is being tested?
- TXI mode vs. WLE mode
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 80 participants
- Where
- 1 siteGermany
- Study dates
- 8 May 2024to Sep 2025
- Phase
- Interventional
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- No healthy volunteers
- Adult, Older adult
Who may be able to join
- Histologically confirmed inflammatory bowel disease (ulcerative colitis or Crohn\'s disease)
- Age ≥ 18 years
Who cannot join
- Post (procto-) colectomy
- Endoscopically impassable stenosis in the left hemi-colon
- ASA status \> 2 points
- BBPS \< 6 points (or \< 2 points per segment)
- Severe coagulation disorder
- Pregnancy, lactation
Trial locations and contacts
1 site in 1 country. Contact the study team or a site near you to ask about taking part.
Anna Melzer, Dr. med. contact
Germany1 site, 1 recruiting
- Recruiting
Ulm University Hospital
Ulm, Baden-Wurttemberg, 89081
Anna Melzer, Dr. med., +4917315000, anna.melzer@uniklinik-ulm.de
About this study
Official title: Texture and Color Enhancement Imaging (TXI) for Real-time Prediction of Histologic Changes in Patients With Inflammatory Bowel Diseases: a Comparison of White Light Endoscopy (WLE) Versus TXI
In the context of the COLORIZE study, it is being tested whether the endoscopic light mode Texture and Color Enhancement Imaging (TXI) is non-inferior to the standard White Light Endoscopy (WLE) in assessing inflammatory activity in patients with Inflammatory Bowel Disease (IBD). For this purpose, ileocolonoscopy is performed on patients diagnosed with IBD, and standardized image documentation will be carried out in both WLE and TXI modes. Step biopsies are taken, and clinically validated, endoscopic, and histological scores are used.
Read the detailed description
In order to make meaningful therapy decisions for patients with IBD, regular assessment of the extent of intestinal inflammation is necessary. This is particularly true for patients with Crohn\'s disease, as the inflammatory activity often does not correspond adequately to the symptoms described by the patient. Therefore, inflammatory activity is assessed not only at the time of diagnosis and during follow-up based on history, physical examination, and laboratory tests, but also through regular endoscopic examinations. The available endoscopic scores for assessing IBD were developed and validated based on the standard light setting, known as White Light Endoscopy (WLE). However, there is inadequate correlation between these scores and the most commonly used histological IBD scores. In recent years, in addition to WLE, other endoscopy modes developed for image optimization have been used for macroscopic assessment of IBD. An example of a new image-enhancing endoscopy mode is Texture and Color Enhancement Imaging (TXI; Olympus Corporation, Tokyo, Japan). The TXI mode is a directly switchable image mode on the endoscope, so it can be performed without special preparation or staining of the intestinal mucosa. Only the generated endoscopy image is digitally processed. With this endoscopy module, brightness in dark areas of an endoscopic image is selectively increased, color and surface structure are improved, making subtle tissue differences such as minor color changes more visible. There are only limited data on the use of the TXI mode for endoscopic assessment of the intestinal mucosa in patients with IBD. Only a single-center study has been conducted, which included 146 patients with ulcerative colitis, aiming to evaluate the presence of mucosal healing using WLE and TXI. In this study, the TXI mode appeared to be superior to WLE in detecting inflammatory lesions. Since an endoscopy score (so-called TXI score) that has not yet been validated in larger cohorts was used in this study, comparability between WLE and TXI has not been established. Therefore, the present project hypothesizes that predicting inflammatory activity at the histological level using the TXI mode is at least as good as using conventional WLE. Crucially, the same endoscopic score is used for both modes (TXI and WLE). Successful implementation of this research question could improve the diagnosis and monitoring of IBD patients. Moreover, if the TXI mode proves superior to WLE, it could lead to a reduction in the number of intestinal biopsies required for diagnosis, resulting in significant savings in personnel and financial resources.
The aim of the study COLORIZE is to assess the non-inferiority of TXI compared to WLE in predicting histological changes in IBD using the area under the curve (AUC) as a measure of prognostic accuracy. The hypothesis to be tested in this study is: There is no difference in the assessment of inflammatory activity in the colon and terminal ileum in chronic inflammatory bowel diseases (CED) between the TXI mode and White Light Endoscopy (WLE) when the AUC of the TXI mode (AUC_TXI) is less than the AUC of WLE (AUC_WLE) minus the non-inferiority margin δ. The null hypothesis H0 states: AUC_TXI \< AUC_WLE - δ, while the alternative hypothesis H1 states that AUC_TXI ≥ AUC_WLE - δ.
A prospective, crossover study is being conducted. A total of 80 patients diagnosed with chronic inflammatory bowel disease and scheduled for outpatient ileocolonoscopy are included. After the legally required informed consent process, participating patients are asked to undertake the necessary preparation or bowel cleansing measures at home for the ileocolonoscopy.
The study consists of four parts:
Part 1: Before the start of the endoscopic examination, the patient\'s medical IBD therapy (current therapy and therapy of the past 12 months), current GI symptoms, and any previous GI surgeries are recorded and documented in writing using a patient questionnaire. Subsequently, an ileocolonoscopy is performed. During the withdrawal of the endoscope, the intestinal mucosa (mucosa) is assessed using the endoscopic light settings WLE and TXI. The macroscopic assessment includes the following five Regions of Interest (ROI): terminal or neo-terminal ileum, ascending colon, transverse colon, descending colon/sigmoid, rectum. One biopsy taken in all five ROI, and if necessary, additional biopsies are taken from macroscopically inflamed mucosa regardless of the ROI. Photodocumentation is performed during the examination (During the examination, at least three photos are saved per ROI, consisting of an overview photo in WLE, WLE close (close means closer to the intestinal mucosa) and TXI close). With the exception of the TXI photos, this corresponds to the standard procedure of \"step biopsies\" in IBD.
Part 2: Endoscopic scores (MES for ulcerative colitis, SES-CD for Crohn\'s disease) are determined for WLE and separately for TXI based on the photodocumentation taken during the ileocolonoscopy. Endoscopic scoring based on WLE is done by unblinded assessor 1 immediately after the examination. After completion of all ileocolonoscopies (n = 80), the entire stored image material (WLE and TXI) is re-evaluated by seven examiners, three of whom had performed a part of the ileocolonoscopies. The inflammatory activity should be assessed per photo on a scale of "inactive, mild, moderate and severe". The endoscopy photos are presented free of patient data and in random order to avoid recognition of the examinations performed by the examiners themselves.
Part 3: Pathologists at the University Hospital Ulm determine histological scores based on the collected intestinal biopsies (Geboes for ulcerative colitis, GHAS for Crohn\'s disease).
Part 4: The prognostic quality of TXI vs. WLE is tested using ROC curves, initially binary (inflammation vs. no inflammation). In secondary analyses, the degree of inflammation is also taken into account according to the scores obtained. The histological score is used as the gold standard.
Extended patient follow-up beyond the ileocolonoscopy procedure with biopsy collection is not necessary beyond the standard follow-up for a routine ileocolonoscopy.
- Being tested
- TXI mode vs. WLE mode
- Keywords
- TXI, Inflammatory Bowel Diseases
- Medical subject headings
- Inflammatory Bowel Diseases, Colitis, Ulcerative, Crohn Disease
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
TXI mode vs. WLE modeDiagnostic test
Experimental use of TXI mode compared to standard use of WLE to assess inflammatory activity in patients with IBD during ileocolonoscopy. Both endoscopy modes are used during the same ileocolonoscopy on the same patient.
| Study group | Role | What they receive |
|---|---|---|
| TXI mode vs. WLE mode | Experimental | Use of TXI mode vs. WLE mode for evaluating the degree of inflammation during ileocolonoscopy. Both endoscopy modes are used during the same ileocolonoscopy on the same patient. Photo documentation is taken in both modes. Receives: Diagnostic Test: TXI mode vs. WLE mode |
What is being measured
The primary outcome is the main question the study is designed to answer.
Non-inferiority of the TXI mode in assessing the degree of inflammation in the correlation between endoscopic and histological scores.
Non-inferiority of the TXI mode compared to WLE assessing inflammation in the terminal ileum or neo-terminal ileum as well as in the colon is evaluated via endoscopic and histologic scores.
Measured: up to 12 months
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted25 Mar 2025
- Study start8 May 2024
- Primary completion31 Mar 2025
- Study completionSep 2025 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Inflammatory Bowel DiseasesStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Diagnosis
- Allocation
- Not applicable
- Intervention model
- Single group
- Model description
- This is a single-group crossover study, as the two endoscopic light modes, TXI and WLE, are alternated within the same examination in the same patients.
- Masking
- None (open label)
- Enrolment
- 80 participants (estimated)
Sponsor and investigators
- Lead sponsor
- University of Ulm
- Sponsor type
- University, hospital or other
- Responsible party
- Principal investigator, Thomas Seufferlein, University of Ulm
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT06892990
- Sponsor's protocol ID
- COLORIZE
- Acronym
- COLORIZE
- Status last verified
- Apr 2025
- First submitted
- 25 Sep 2024
- Last updated
- 2 May 2025
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No
Study at a glance
From the registry record, last updated by the sponsor on 2 May 2025. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Texture and Color Enhancement Imaging (TXI) for Real-time Prediction of Histologic Changes in Patients With Inflammatory Bowel Diseases: a Comparison of White Light Endoscopy (WLE) Versus TXI
- ClinicalTrials.gov ID
- NCT06892990
- Acronym / sponsor ID
- COLORIZE / COLORIZE
- Keywords
- TXI, Inflammatory Bowel Diseases
- Study type
- Interventional
- Recruitment status
- Recruiting
- Enrolment
- 80 participants (estimated)
- Lead sponsor
- University of UlmUniversity, hospital or other
- Study start
- 8 May 2024 (actual)
- Primary completion
- 31 Mar 2025 (actual)
- Study completion
- Sep 2025 (estimated)
- First posted
- 25 Mar 2025 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
In the context of the COLORIZE study, it is being tested whether the endoscopic light mode Texture and Color Enhancement Imaging (TXI) is non-inferior to the standard White Light Endoscopy (WLE) in assessing inflammatory activity in patients with Inflammatory Bowel Disease (IBD). For this purpose, ileocolonoscopy is performed on patients diagnosed with IBD, and standardized image documentation will be carried out in both WLE and TXI modes. Step biopsies are taken, and clinically validated, endoscopic, and histological scores are used.
Detailed description
In order to make meaningful therapy decisions for patients with IBD, regular assessment of the extent of intestinal inflammation is necessary. This is particularly true for patients with Crohn\'s disease, as the inflammatory activity often does not correspond adequately to the symptoms described by the patient. Therefore, inflammatory activity is assessed not only at the time of diagnosis and during follow-up based on history, physical examination, and laboratory tests, but also through regular endoscopic examinations. The available endoscopic scores for assessing IBD were developed and validated based on the standard light setting, known as White Light Endoscopy (WLE). However, there is inadequate correlation between these scores and the most commonly used histological IBD scores. In recent years, in addition to WLE, other endoscopy modes developed for image optimization have been used for macroscopic assessment of IBD. An example of a new image-enhancing endoscopy mode is Texture and Color Enhancement Imaging (TXI; Olympus Corporation, Tokyo, Japan). The TXI mode is a directly switchable image mode on the endoscope, so it can be performed without special preparation or staining of the intestinal mucosa. Only the generated endoscopy image is digitally processed. With this endoscopy module, brightness in dark areas of an endoscopic image is selectively increased, color and surface structure are improved, making subtle tissue differences such as minor color changes more visible. There are only limited data on the use of the TXI mode for endoscopic assessment of the intestinal mucosa in patients with IBD. Only a single-center study has been conducted, which included 146 patients with ulcerative colitis, aiming to evaluate the presence of mucosal healing using WLE and TXI. In this study, the TXI mode appeared to be superior to WLE in detecting inflammatory lesions. Since an endoscopy score (so-called TXI score) that has not yet been validated in larger cohorts was used in this study, comparability between WLE and TXI has not been established. Therefore, the present project hypothesizes that predicting inflammatory activity at the histological level using the TXI mode is at least as good as using conventional WLE. Crucially, the same endoscopic score is used for both modes (TXI and WLE). Successful implementation of this research question could improve the diagnosis and monitoring of IBD patients. Moreover, if the TXI mode proves superior to WLE, it could lead to a reduction in the number of intestinal biopsies required for diagnosis, resulting in significant savings in personnel and financial resources.
The aim of the study COLORIZE is to assess the non-inferiority of TXI compared to WLE in predicting histological changes in IBD using the area under the curve (AUC) as a measure of prognostic accuracy. The hypothesis to be tested in this study is: There is no difference in the assessment of inflammatory activity in the colon and terminal ileum in chronic inflammatory bowel diseases (CED) between the TXI mode and White Light Endoscopy (WLE) when the AUC of the TXI mode (AUC_TXI) is less than the AUC of WLE (AUC_WLE) minus the non-inferiority margin δ. The null hypothesis H0 states: AUC_TXI \< AUC_WLE - δ, while the alternative hypothesis H1 states that AUC_TXI ≥ AUC_WLE - δ.
A prospective, crossover study is being conducted. A total of 80 patients diagnosed with chronic inflammatory bowel disease and scheduled for outpatient ileocolonoscopy are included. After the legally required informed consent process, participating patients are asked to undertake the necessary preparation or bowel cleansing measures at home for the ileocolonoscopy.
The study consists of four parts:
Part 1: Before the start of the endoscopic examination, the patient\'s medical IBD therapy (current therapy and therapy of the past 12 months), current GI symptoms, and any previous GI surgeries are recorded and documented in writing using a patient questionnaire. Subsequently, an ileocolonoscopy is performed. During the withdrawal of the endoscope, the intestinal mucosa (mucosa) is assessed using the endoscopic light settings WLE and TXI. The macroscopic assessment includes the following five Regions of Interest (ROI): terminal or neo-terminal ileum, ascending colon, transverse colon, descending colon/sigmoid, rectum. One biopsy taken in all five ROI, and if necessary, additional biopsies are taken from macroscopically inflamed mucosa regardless of the ROI. Photodocumentation is performed during the examination (During the examination, at least three photos are saved per ROI, consisting of an overview photo in WLE, WLE close (close means closer to the intestinal mucosa) and TXI close). With the exception of the TXI photos, this corresponds to the standard procedure of \"step biopsies\" in IBD.
Part 2: Endoscopic scores (MES for ulcerative colitis, SES-CD for Crohn\'s disease) are determined for WLE and separately for TXI based on the photodocumentation taken during the ileocolonoscopy. Endoscopic scoring based on WLE is done by unblinded assessor 1 immediately after the examination. After completion of all ileocolonoscopies (n = 80), the entire stored image material (WLE and TXI) is re-evaluated by seven examiners, three of whom had performed a part of the ileocolonoscopies. The inflammatory activity should be assessed per photo on a scale of "inactive, mild, moderate and severe". The endoscopy photos are presented free of patient data and in random order to avoid recognition of the examinations performed by the examiners themselves.
Part 3: Pathologists at the University Hospital Ulm determine histological scores based on the collected intestinal biopsies (Geboes for ulcerative colitis, GHAS for Crohn\'s disease).
Part 4: The prognostic quality of TXI vs. WLE is tested using ROC curves, initially binary (inflammation vs. no inflammation). In secondary analyses, the degree of inflammation is also taken into account according to the scores obtained. The histological score is used as the gold standard.
Extended patient follow-up beyond the ileocolonoscopy procedure with biopsy collection is not necessary beyond the standard follow-up for a routine ileocolonoscopy.
Study design
- Primary purpose
- Diagnosis
- Allocation
- Not applicable
- Intervention model
- Single group
- Masking
- None (open label)
- Number of arms
- 1
- Model description
- This is a single-group crossover study, as the two endoscopic light modes, TXI and WLE, are alternated within the same examination in the same patients.
| Arm | Type | Receives |
|---|---|---|
| TXI mode vs. WLE mode | Experimental | Diagnostic Test: TXI mode vs. WLE modeUse of TXI mode vs. WLE mode for evaluating the degree of inflammation during ileocolonoscopy. Both endoscopy modes are used during the same ileocolonoscopy on the same patient. Photo documentation is taken in both modes. |
Who may qualify
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (2 listed)
- Histologically confirmed inflammatory bowel disease (ulcerative colitis or Crohn\'s disease)
- Age ≥ 18 years
Key exclusion criteria (6 listed)
- Post (procto-) colectomy
- Endoscopically impassable stenosis in the left hemi-colon
- ASA status \&gt; 2 points
- BBPS \&lt; 6 points (or \&lt; 2 points per segment)
- Severe coagulation disorder
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| TXI mode vs. WLE modeExperimental use of TXI mode compared to standard use of WLE to assess inflammatory activity in patients with IBD during ileocolonoscopy. Both endoscopy modes are used during the same ileocolonoscopy on the same patient. | Diagnostic test | TXI mode vs. WLE mode |
Primary outcome
Non-inferiority of the TXI mode in assessing the degree of inflammation in the correlation between endoscopic and histological scores.
Time frame: up to 12 months
Non-inferiority of the TXI mode compared to WLE assessing inflammation in the terminal ileum or neo-terminal ileum as well as in the colon is evaluated via endoscopic and histologic scores.
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 2 May 2025.
- Individual participant dataSharing planned: No
Related trials for Inflammatory Bowel Diseases
Not yet recruitingPhase 1
An Open-label, DDI Study to Investigate the Effects of Duvakitug on the PK of Selected Cytochrome P450 Substrates
Ulcerative Colitis, Crohn's Disease
RecruitingObservational study
Longitudinal Immunophenotyping of Patients With Inflammatory Bowel Disease
Inflammatory Bowel Disease, Crohn's Disease
RecruitingObservational study
Ibd CAncer and seRious Infections in France (I-CARE 2)
IBD, Ulcerative Colitis
RecruitingObservational study
Multidimensional Dynamic Early Warning System for Neonatal Necrotizing Enterocolitis: A Multicenter Clinical Study
NEC - Necrotizing Enterocolitis
Recruiting
Effect of Mediterranean Diet in Inflammatory Bowel Disease
Inflammatory Bowel Disease
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
Anna Melzer, Dr. med. contact
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing TXI mode vs. WLE mode in people with Inflammatory Bowel Diseases and Colitis, Ulcerative, run by University of Ulm at 1 site in Germany.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 2 inclusion and 6 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: looking for participants now, as of the sponsor's last update on 2 May 2025. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Germany. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
Contact Benjamin Michael Walter, Prof. Dr. med. (+497315000, benjamin.walter@uniklinik-ulm.de), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Non-inferiority of the TXI mode in assessing the degree of inflammation in the correlation between endoscopic and histological scores. (time frame: up to 12 months). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 2 May 2025.